| Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
|---|
| Scopolamine | hsa00020 | Citrate cycle (TCA cycle) | 3.41E-02 | 2 | P50213, O14521 | IDH3A, SDHD | More | | | Scopolamine | hsa00071 | Fatty acid degradation | 3.77E-02 | 3 | O75521, P11766, P33121 | ECI2, ADH5, ACSL1 | More | | | Scopolamine | hsa00190 | Oxidative phosphorylation | 2.11E-04 | 3 | Q16718, Q13488, O14521 | NDUFA5, TCIRG1, SDHD | More | | | Scopolamine | hsa00500 | Starch and sucrose metabolism | 2.10E-02 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | | Scopolamine | hsa00970 | Aminoacyl-tRNA biosynthesis | 9.32E-03 | 3 | O95363, P54136, Q15046 | FARS2, RARS1, KARS | More | | | Scopolamine | hsa01230 | Biosynthesis of amino acids | 3.91E-02 | 3 | P51854, Q99707, P50213 | TKTL1, MTR, IDH3A | More | | | Scopolamine | hsa02010 | ABC transporters | 2.29E-02 | 2 | P45844, P08183 | ABCG1, ABCB1 | More | | | Scopolamine | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | | | Scopolamine | hsa04080 | Neuroactive ligand-receptor interaction | 3.70E-02 | 7 | P08311, P48058, Q15722, Q9H228, P43657, P21730, P35318 | CTSG, GRIA4, LTB4R, EDG8, P2RY5, C5AR1, ADM | More | | | Scopolamine | hsa04213 | Longevity regulating pathway - multiple species | 2.85E-02 | 2 | Q9Y4H2, Q13547 | IRS2, HDAC1 | More | | | Scopolamine | hsa04613 | Neutrophil extracellular trap formation | 3.76E-04 | 10 | P11215, Q13547, P04908, Q93077, P58876, Q16778, O60814, P68431, O43315, Q16539 | ITGAM, HDAC1, H2AC4; H2AC8, HIST1H2AC, H2BC5, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, AQP9, MAPK14 | More | | | Scopolamine | hsa04640 | Hematopoietic cell lineage | 1.13E-02 | 8 | P13612, P14778, P27930, P15144, P07766, P09693, P01732, P01730 | ITGA4, IL1R1, IL1R2, ANPEP, CD3E, CD3G, CD8A, CD4 | More | | | Scopolamine | hsa04650 | Natural killer cell mediated cytotoxicity | 2.05E-03 | 9 | P78314, P06239, O60880, P20963, Q13241, P26718, O75015, P26717, P26715 | SH3BP2, LCK, SH2D1A, CD247, KLRD1, KLRK1, FCGR3B, KLRC2, KLRC1 | More | | | Scopolamine | hsa04658 | Th1 and Th2 cell differentiation | 1.27E-04 | 9 | Q04759, P07766, P20963, P09693, Q16539, P01730, P06239, P23771, Q9UL17 | PRKCQ, CD3E, CD247, CD3G, MAPK14, CD4, LCK, GATA3, TBX21 | More | | | Scopolamine | hsa04659 | Th17 cell differentiation | 1.64E-04 | 10 | Q04759, Q16539, P01730, P06239, P14778, Q9UL17, P23771, P07766, P09693, P20963 | PRKCQ, MAPK14, CD4, LCK, IL1R1, TBX21, GATA3, CD3E, CD3G, CD247 | More | | | Scopolamine | hsa04660 | T cell receptor signaling pathway | 6.29E-04 | 10 | Q04759, P07766, P20963, P09693, P01730, P01732, Q13191, P06239, Q16539, P49841 | PRKCQ, CD3E, CD247, CD3G, CD4, CD8A, CBLB, LCK, MAPK14, GSK3B | More | | | Scopolamine | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | | | Scopolamine | hsa04721 | Synaptic vesicle cycle | 1.80E-02 | 2 | Q13488, P31645 | TCIRG1, SLC6A4 | More | | | Scopolamine | hsa04932 | Non-alcoholic fatty liver disease | 3.62E-02 | 3 | P49841, Q16718, O14521 | GSK3B, NDUFA5, SDHD | More | | | Scopolamine | hsa04976 | Bile secretion | 3.32E-02 | 2 | O43315, P08183 | AQP9, ABCB1 | More | | | Scopolamine | hsa05020 | Prion disease | 3.80E-02 | 4 | Q16718, O14521, P49841, Q16539 | NDUFA5, SDHD, GSK3B, MAPK14 | More | | | Scopolamine | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.24E-02 | 6 | P49841, Q16718, O14521, Q13561, Q16539, Q08752 | GSK3B, NDUFA5, SDHD, DCTN2, MAPK14, PPID | More | | | Scopolamine | hsa05034 | Alcoholism | 2.10E-03 | 4 | Q13547, P58876, Q16778, O60814 | HDAC1, H2BC5, HIST2H2BE, H2BC12 | More | | | Scopolamine | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 3.76E-02 | 4 | Q16539, P09341, P25024, P25025 | MAPK14, CXCL1, CXCR1, CXCR2 | More | | | Scopolamine | hsa05135 | Yersinia infection | 1.52E-02 | 6 | P13612, P06239, Q16539, P49841, P01730, P01732 | ITGA4, LCK, MAPK14, GSK3B, CD4, CD8A | More | | | Scopolamine | hsa05140 | Leishmaniasis | 4.50E-03 | 5 | P14598, O60603, P25963, P29350, Q15080 | NCF1, TLR2, NFKBIA, PTPN6, NCF4 | More | | | Scopolamine | hsa05146 | Amoebiasis | 2.10E-02 | 6 | P09341, P14778, P27930, P05089, P12814, P08311 | CXCL1, IL1R1, IL1R2, ARG1, ACTN1, CTSG | More | | | Scopolamine | hsa05202 | Transcriptional misregulation in cancer | 1.24E-02 | 4 | P27930, P11215, Q13547, P12980 | IL1R2, ITGAM, HDAC1, LYL1 | More | | | Scopolamine | hsa05203 | Viral carcinogenesis | 6.44E-03 | 4 | Q13547, P58876, Q16778, O60814 | HDAC1, H2BC5, HIST2H2BE, H2BC12 | More | | | Scopolamine | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 4.79E-03 | 7 | P07766, P20963, P09693, P06239, Q04759, Q16539, P01730 | CD3E, CD247, CD3G, LCK, PRKCQ, MAPK14, CD4 | More | | | Scopolamine | hsa05322 | Systemic lupus erythematosus | 1.18E-02 | 3 | P58876, Q16778, O60814 | H2BC5, HIST2H2BE, H2BC12 | More | | | Scopolamine | hsa05340 | Primary immunodeficiency | 3.76E-02 | 4 | P01730, P01732, P07766, P06239 | CD4, CD8A, CD3E, LCK | More | | | Scopolamine | hsa05415 | Diabetic cardiomyopathy | 1.28E-02 | 4 | Q16718, O14521, Q16539, P49841 | NDUFA5, SDHD, MAPK14, GSK3B | More | |
|
